Vermillion Announces OVA1® (MIA) and OVERA® (MIA2G) Study and Coverage ... - GlobeNewswire (press release)

Vermillion Announces OVA1® (MIA) and OVERA® (MIA2G) Study and Coverage ...
GlobeNewswire (press release)
AUSTIN, Texas, Nov. 08, 2018 (GLOBE NEWSWIRE) -- Vermillion, Inc. (NASDAQ: VRML), a bioanalytical-based women's health company focused on gynecologic disease, today announced a study agreement and coverage with Clalit Health Services in ...en meer »